Regulatory approval

Published by the Health Service Executive. Approved

In combination with riTUXimab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) as first line treatment in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies.

This is written in the approval document.

Reimbursement

Hybrid

Idelalisib - CDS; riTUXimab - Hospital

Citation

Idelalisib and riTUXimab Therapy, 2017, version number 1, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6972/389_v3_idelalisib_and_riTUXimab.pdf

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
HSE (1)	TP53 deletion	Chronic Lymphocytic Leukemia	Idelalisib, Rituximab
HSE (1)	TP53 Somatic variants	Chronic Lymphocytic Leukemia	Idelalisib, Rituximab
HSE (1)	17p deletion	Chronic Lymphocytic Leukemia	Idelalisib, Rituximab

Contributions

Date	Contributor	Description
2024-01-16	Van Allen lab	Adding HSE approvals for reimbursement to database
2017-01-05	Health Service Executive	Indication approved for reimbursement.